Exeliom Biosciences has been awarded a 2.5M€ H2020 Accelerator Program Grant from the European Innovation Council

This very selective grant will help Exeliom Biosciences obtain first clinical readouts and achieve the manufacturing process scale-up, while protecting its proprietary know-how. With this EIC support, Exeliom Biosciences will be able to greatly accelerate its promising drug development and growth.

Back to news

#HealthcareInnovation #ClinicalTrial #CDI #Partnership #ExeliomBiosciences #HospicesCivilsdeLyon #MedicalResearch #HealthcareInnovation #ExeliomBiosciences #Biotech #Start-up #Microbiome #Cdiff

Nov 6, 2023

Exeliom Biosciences and Hospices Civils de Lyon announce clinical collaboration in recurrent Clostridioides difficile infection

Explore

#funding #SeriesA #Clinicaltrials

Jun 30, 2023

Exeliom Biosciences Announces Series A Extension and Final Closing with Total of €24 Million ($26 Million) to Progress the Clinical Development of its Lead Candidate in Immuno-Oncology and Infectious Diseases.

Explore

Apr 27, 2023

SATT Paris-Saclay and Exeliom Biosciences Sign License Option Agreement to Develop Breakthrough Recombinant Protein Targeting Tryptophan Metabolism

Explore

Exeliom Biosciences has been awarded a 2.5M€ H2020 Accelerator Program Grant from the European Innovation Council

contact